Form 4: June Sherie Almenoff Cancels Stock Options in Actinium Pharmaceuticals
SEC Form 4
Director June Sherie Almenoff cancels stock options to purchase 50,000 shares of Actinium Pharmaceuticals common stock effective March 31, 2025.
Summary
- June Sherie Almenoff, a director of Actinium Pharmaceuticals, Inc., has cancelled stock options.
- The cancellation involved options to purchase 50,000 shares of common stock.
- The transaction was effective as of March 31, 2025.
- The cancellation was made pursuant to an Option Cancellation and Release Agreement in exchange for nominal consideration.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing regarding the cancellation of stock options. It doesn't inherently convey positive or negative sentiment.
Future Outlook
The document does not contain any forward-looking statements or guidance.
Industry Context
This filing reflects insider activity related to stock options, which is a common practice in publicly traded companies. Option cancellations can occur for various reasons, including changes in employment or agreements between the company and the individual.
Stakeholder Impact
- The cancellation of stock options may have a minor impact on the total number of outstanding options, potentially affecting shareholder dilution.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of earliest transaction and effective date of stock option cancellation. |
| 04/02/2025 | Date of signature on the Form 4 filing. |
| 11/01/2034 | Original expiration date of the cancelled stock options. |
Keywords
stock options, Actinium Pharmaceuticals, director, cancellation, ATNM, June Sherie Almenoff
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.